Regenxbio Inc (RGNX)
11.14
+0.47
(+4.40%)
USD |
NASDAQ |
Nov 14, 16:00
11.58
+0.44
(+3.95%)
After-Hours: 20:00
Regenxbio Gross Profit (Annual): 53.03M for Dec. 31, 2023
Gross Profit (Annual) Chart
Historical Gross Profit (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 53.03M |
| December 31, 2022 | 58.18M |
| December 31, 2021 | 418.51M |
| December 31, 2020 | 118.85M |
| December 31, 2019 | 26.99M |
| December 31, 2018 | 208.86M |
| Date | Value |
|---|---|
| December 31, 2017 | 8.684M |
| December 31, 2016 | 3.63M |
| December 31, 2015 | 6.085M |
| December 31, 2014 | 5.113M |
| December 31, 2013 | 5.763M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (Annual) Range, Past 5 Years
26.99M
Minimum
2019
418.51M
Maximum
2021
135.11M
Average
58.18M
Median
2022
Gross Profit (Annual) Benchmarks
| Catalyst Pharmaceuticals Inc | 346.24M |
| EyePoint Pharmaceuticals Inc | 41.39M |
| Cassava Sciences Inc | -- |
| Vertex Pharmaceuticals Inc | 8.607B |
| Sarepta Therapeutics Inc | 1.093B |